Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 18/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 13/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 13/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340689 | 0.81 | CHRNA4 (0.61) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3330785 | 0.80 | CHRNA4 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3335053 | 0.79 | CHRNA4 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3337517 | 0.78 | CHRNA4 (0.60) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3337805 | 0.74 | CHRNA4 (0.56) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3334139 | 0.74 | CHRNA4 (0.59) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3334856 | 0.74 | CHRNA4 (0.60) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3332578 | 0.73 | CHRNA4 (0.61) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3334135 | 0.72 | CHRNB2 (0.60) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3337021 | 0.72 | CHRNA4 (0.84) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CHRNA4 8/4885CHRNB2 4/4885CHRNB4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.